Drug repurposing approach to fight COVID-19
Currently, there are no treatment options available for the deadly contagious disease,
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
COVID-19 in immunocompromised hosts: what we know so far
M Fung, JM Babik - Clinical Infectious Diseases, 2021 - academic.oup.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and …
respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused significant morbidity and …
Emerging treatment strategies for COVID-19 infection
M Gavriatopoulou, I Ntanasis-Stathopoulos… - Clinical and …, 2021 - Springer
The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and
has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused …
has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused …
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
P Vizcarra, MJ Pérez-Elías, C Quereda, A Moreno… - The lancet HIV, 2020 - thelancet.com
Background Information about incidence, clinical characteristics, and outcomes of HIV-
infected individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
infected individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Potent noncovalent inhibitors of the main protease of SARS-CoV-2 from molecular sculpting of the drug perampanel guided by free energy perturbation calculations
Starting from our previous finding of 14 known drugs as inhibitors of the main protease
(Mpro) of SARS-CoV-2, the virus responsible for COVID-19, we have redesigned the weak …
(Mpro) of SARS-CoV-2, the virus responsible for COVID-19, we have redesigned the weak …
Hydroxychloroquine for early treatment of adults with mild coronavirus disease 2019: a randomized, controlled trial
O Mitjà, M Corbacho-Monné, M Ubals… - Clinical Infectious …, 2021 - academic.oup.com
Background No effective treatments for coronavirus disease 2019 (COVID-19) exist. We
aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be …
aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be …
SARS-CoV-2 antiviral therapy
The development of effective antiviral therapy for COVID-19 is critical for those awaiting
vaccination, as well as for those who do not respond robustly to vaccination. This review …
vaccination, as well as for those who do not respond robustly to vaccination. This review …
Immune deficiency is a risk factor for severe COVID‐19 in people living with HIV
C Hoffmann, JL Casado, G Härter, P Vizcarra… - HIV …, 2021 - Wiley Online Library
Objectives A prior T cell depletion induced by HIV infection may carry deleterious
consequences in the current COVID‐19 pandemic. Clinical data on patients co‐infected with …
consequences in the current COVID‐19 pandemic. Clinical data on patients co‐infected with …
Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies
Severe acute respiratory disease coronavirus 2 (SARS-CoV-2, formerly 2019-nCoV) is a
novel coronavirus that has rapidly disseminated worldwide, causing the coronavirus disease …
novel coronavirus that has rapidly disseminated worldwide, causing the coronavirus disease …
A review of potential suggested drugs for coronavirus disease (COVID-19) treatment
The latest pandemic, coronavirus disease-2019 (COVID-19), is associated with high
prevalence and easy transmission, which is expanding globally with no conventional …
prevalence and easy transmission, which is expanding globally with no conventional …